Phase 2 N=35 Studying Amphetamine Withdrawal in Humans
Methamphetamine Dependence
Primary: Measure of Methamphetamine Withdrawal — 3.7283; 10.056 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=127 Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
ADHD
Primary: Lean Squares Mean (± Standard Error) of Math Test Score Over All Post-dose Time Points (0.5, 1, 2, 4, 8, 10, 12, 13, and 14 Hours Post-dose) Assessed During the…
N/A N=24 Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD
Obsessive-Compulsive Disorder
Primary: Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2 — 6; 7 participants
Early Phase 1 N=18 Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
Active Cocaine Users
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Phase 2 N=81 A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence
Cocaine Dependence
Primary: Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back — 13; 7 participants — p==.05
Phase 2 N=73 Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…
Phase 4 N=40 Effects of Modafinil in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Percentage of Participants With Methamphetamine-positive Urine Drug Screens — 85; 65 Percentage of participants
Phase 3 N=403 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder
Methamphetamine Use Disorder
Primary: Number of Participants With Treatment Response During Medication Phase at Stage 1 — 10; 18; 284; 91 Participants
Phase 3 N=320 Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms — -11.1; -18.2; -18.1 score on a scale
Phase 2 N=20 Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity · Cocaine-Related Disorders
Primary: the Adult ADHD Rating Scale (AARS) (30% Reduction) — 50 percent of participants
Phase 2 N=13 Clinical Efficacy of Atomoxetine for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Time Till Relapse — 7; -8 Days to Relapse — p=<0.05
Phase 3 N=126 Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
Adult Attention Deficit Hyperactivity Disorder · Cocaine Dependence
Primary: Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use — 7; 18; 30 percentage of participants
Phase 3 N=28 Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder
Cannabis Use Disorder · Attention-deficit/Hyperactivity Disorder
Primary: Marijuana Abstinence — 0; 2 Participants
Phase 2 N=71 Modafinil vs Placebo for the Treatment of Methamphetamine Dependence
Methamphetamine Dependence
Primary: Clean Urine Drug Screen — 13.1; 12.7 Clean urine drug screens
N/A N=18 Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility
Attention Deficit Hyperactivity Disorder
Primary: Change in Adult ADHD Investigator Symptom Rating Scale Score — 17.3 units on a scale
Phase 4 N=41 Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
Major Depressive Disorder
Primary: Change in Scores on the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (MGH-CPFQ) — 27.5; 29; 22.6; 25 Scores on a scale
Phase 3 N=127 Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
Cocaine Dependence
Primary: Three Weeks of Cocaine Abstinence at End of Study — 9; 0 Participants
Phase 2 N=15 Open-Label Disulfiram for Methamphetamine Dependence
Methamphetamine Dependence
Primary: Side Effects Checklist — 9.6515 units on a scale — p=0.05
Phase 3 N=100 Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland
Amphetamine Dependence
Primary: Number Negative Urines (Proportion Negative Urines) — 560; 634 Urine Drug Screen
N/A N=60 A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
Amphetamine Abuse · Amphetamine Dependence · Bipolar Disorder
Primary: Depression Symptoms — 26.2; 33.1 scores on a scale — p=0.05
N/A N=40 Bupropion in the Treatment of Methamphetamine Dependence
Methamphetamine Use Disorder
Primary: Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence. — 5.6; 6.0 days
N/A N=8 Characterizing Methamphetamine Withdrawal in Recently Abstinent Methamphetamine Users: A Pilot Study
Methamphetamine Dependence · Methamphetamine Withdrawal
Primary: Methamphetamine Selective Severity Assessment (MSSA) — 48.2 "units on a scale" — p=<0.05
Phase 2 N=140 Topiramate for the Treatment of Methamphetamine Dependence - 1
Methamphetamine
Primary: Abstinence (Weeks 6 - 12) — 49; 49; 43; 48 Participants
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…
Phase 4 N=33 Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder
Attention Deficit Disorder With Hyperactivity · Conduct Disorder · Substance Abuse
Primary: Change in fMRI Measure — -0.957100; 0.572517; -0.139000; 1.876717 BOLD signal
Phase 1 N=12 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Phase 1 N=9 Buspirone as a Candidate Medication for Methamphetamine Abuse
Methamphetamine Dependence · Methamphetamine Abuse
Primary: Number of Methamphetamine Doses Self-Administered — 1.25; 0; 6.13; 4 Number of Methamphetamine Doses
Phase 2 N=43 Treatment of Cocaine Dependence With Lisdexamfetamine
Cocaine Dependence
Primary: Cocaine-positive Urine Results — 86.5; 92.4 percentage of BE urine tests
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale